Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LIQUID BIOPSY MARKET OVERVIEW
• 4.2 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• 4.3 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2025 VS. 2030 (USD MILLION)
• 4.4 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• 4.5 LIQUID BIOPSY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.6 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.7 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.8 LIQUID BIOPSY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing burden of cancer
    • 5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
    • 5.2.1.3 Expanding benefits of liquid biopsy over traditional biopsy procedures
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Lower sensitivity of specific liquid biopsy procedures
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing significance of companion diagnostics
    • 5.2.3.2 Growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Unfavorable reimbursement scenario
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, 2023-2025
  • 5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023-2025
  • 5.3.3 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.7.2 IMPORT DATA (HS CODE 3822)
  • 5.7.3 EXPORT DATA (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 NORTH AMERICA
    • 5.10.2.1 US
    • 5.10.2.2 Canada
  • 5.10.3 EUROPE
  • 5.10.4 ASIA PACIFIC
    • 5.10.4.1 China
    • 5.10.4.2 Japan
    • 5.10.4.3 India
  • 5.10.5 LATIN AMERICA
    • 5.10.5.1 Brazil
    • 5.10.5.2 Mexico
  • 5.10.6 MIDDLE EAST
    • 5.10.6.1 Africa
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Digital Droplet PCR (ddPCR)
    • 5.11.1.2 Tagged-amplicon Deep Sequencing (TAm-Seq)
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Electrochemical biosensing technology
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Microfluidic-based devices
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: DETECTION OF LOW-FREQUENCY MUTATIONS USING TARGET SELECTOR CTDNA TECHNOLOGY
  • 5.16.2 CASE STUDY 2: ANALYTICAL ASSESSMENT OF PLASMA & SERUM FOR CTDNA MUTATION DETECTION
• 5.17 IMPACT OF AI/GENERATIVE AI ON LIQUID BIOPSY MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI USE CASES
  • 5.17.4 FUTURE OF AI IN LIQUID BIOPSY MARKET
• 5.18 TRUMP TARIFF IMPACT ON LIQUID BIOPSY MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 KEY IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Reference laboratories
    • 5.18.5.2 Hospitals & physicians' laboratories
    • 5.18.5.3 Academic & research centers

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 ASSAY KITS
  • 6.2.1 RECURRING PURCHASE TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RISING TECHNOLOGICAL ADVANCES IN DDPCR TO FUEL MARKET
• 6.4 SERVICES
  • 6.4.1 ADOPTION OF CFDNA & CTC TESTING SERVICES TO SUPPORT MARKET GROWTH

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE

• 7.1 INTRODUCTION
• 7.2 CIRCULATING TUMOR DNA
  • 7.2.1 HIGH SENSITIVITY & SPECIFICITY TO PROPEL MARKET
• 7.3 CELL-FREE DNA
  • 7.3.1 BROADENING APPLICATIONS IN PRENATAL SCREENING TO DRIVE MARKET
• 7.4 CIRCULATING TUMOR CELLS
  • 7.4.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMORS TO FUEL MARKET
• 7.5 EXTRACELLULAR VESICLES
  • 7.5.1 HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH
• 7.6 OTHER CIRCULATING BIOMARKERS

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
  • 8.2.1 HIGHER THROUGHPUT EFFICIENCY TO PROPEL MARKET
• 8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
  • 8.3.1 COST-EFFICIENCY AND EASE OF USE TO FUEL UPTAKE

9 LIQUID BIOPSY MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CANCER APPLICATIONS
  • 9.2.1 LUNG CANCER
    • 9.2.1.1 Growing prevalence of lung cancer to propel market
  • 9.2.2 BREAST CANCER
    • 9.2.2.1 Increasing funding investments for breast cancer research to drive market
  • 9.2.3 COLORECTAL CANCER
    • 9.2.3.1 Rising geriatric population to fuel uptake
  • 9.2.4 PROSTATE CANCER
    • 9.2.4.1 Adoption of tumor cell kits to boost demand
  • 9.2.5 MELANOMA
    • 9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market
  • 9.2.6 OTHER CANCERS
• 9.3 NON-CANCER APPLICATIONS
  • 9.3.1 NON-INVASIVE PRENATAL TESTING
    • 9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive market
  • 9.3.2 ORGAN TRANSPLANTATION
    • 9.3.2.1 Early disease diagnosis & detection to support market growth
  • 9.3.3 INFECTIOUS DISEASE TESTING
    • 9.3.3.1 Potential accuracy & efficacy for testing to fuel uptake

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

• 10.1 INTRODUCTION
• 10.2 THERAPY SELECTION
  • 10.2.1 GROWING PREFERENCE FOR PERSONALIZED TREATMENT TO DRIVE MARKET
• 10.3 TREATMENT MONITORING
  • 10.3.1 EARLY DETECTION OF DISEASE PROGRESSION TO BOOST DEMAND
• 10.4 EARLY CANCER SCREENING
  • 10.4.1 GROWING INCIDENCE OF CANCER AND RISING FUNDING INVESTMENTS TO PROPEL MARKET
• 10.5 RECURRENCE MONITORING
  • 10.5.1 RISING NEED FOR POST-TREATMENT SURVEILLANCE TO FUEL UPTAKE

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE

• 11.1 INTRODUCTION
• 11.2 BLOOD SAMPLES
  • 11.2.1 STANDARD SIMPLICITY AND HIGH PATIENT ACCEPTANCE TO PROPEL MARKET
• 11.3 OTHER SAMPLE TYPES

12 LIQUID BIOPSY MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 REFERENCE LABORATORIES
  • 12.2.1 RISING OUTSOURCING OF TESTS AND ABILITY TO UNDERTAKE LARGE SAMPLE VOLUMES TO PROPEL MARKET
• 12.3 HOSPITALS & PHYSICIANS LABORATORIES
  • 12.3.1 INCREASING ESTABLISHMENT OF HOSPITALS TO BOOST DEMAND
• 12.4 ACADEMIC & RESEARCH CENTERS
  • 12.4.1 INCREASING R&D ACTIVITIES FOR INNOVATIVE TESTS TO SUPPORT MARKET GROWTH
• 12.5 OTHER END USERS

13 LIQUID BIOPSY MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 13.2.2 US
    • 13.2.2.1 High healthcare expenditure to propel market
  • 13.2.3 CANADA
    • 13.2.3.1 Availability of various cancer screening programs to drive market
• 13.3 EUROPE
  • 13.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 13.3.2 GERMANY
    • 13.3.2.1 Favorable research funding investments for cancer research to fuel market
  • 13.3.3 UK
    • 13.3.3.1 NHS-funded lab-based disease screening facilities to boost demand
  • 13.3.4 FRANCE
    • 13.3.4.1 Growing focus on expanding access to advanced genomic technologies to drive market
  • 13.3.5 ITALY
    • 13.3.5.1 Development of novel circulating cancer biomarkers to support market growth
  • 13.3.6 SPAIN
    • 13.3.6.1 Focus on personalized medicine to support market uptake
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 13.4.2 CHINA
    • 13.4.2.1 Increasing incidence of infectious diseases to propel market
  • 13.4.3 JAPAN
    • 13.4.3.1 Universal healthcare reimbursement policy to fuel market
  • 13.4.4 INDIA
    • 13.4.4.1 Increasing incidence of chronic diseases and growing focus on early disease diagnosis to drive market
  • 13.4.5 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 13.5.2 BRAZIL
    • 13.5.2.1 Improvements in laboratory infrastructure to drive market
  • 13.5.3 MEXICO
    • 13.5.3.1 Improving accessibility to advanced healthcare services to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 INCREASING COLLABORATIONS & DEVELOPMENTS FOR ENHANCED DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH
  • 13.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
• 14.3 REVENUE ANALYSIS, 2022-2024
• 14.4 MARKET SHARE ANALYSIS
  • 14.4.1 LIQUID BIOPSY MARKET
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product & Service footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of key startups/SMEs, by product & service
    • 14.6.5.3 Competitive benchmarking of key startups/SMEs, by region
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.8.1 BRAND COMPARISON OF PCR-BASED LIQUID BIOPSY ASSAYS
    • 14.8.1.1 QIAGEN N.V.
    • 14.8.1.2 Thermo Fisher Scientific Inc.
    • 14.8.1.3 Bio-Rad Laboratories, Inc.
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 NATERA, INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product/Service launches
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Other developments
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 GUARDANT HEALTH
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product/Service launches & approvals
      • 15.1.2.3.2 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 MYRIAD GENETICS, INC.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product/Service launches
      • 15.1.3.3.2 Deals
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 ILLUMINA, INC.
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product/Service launches & approvals
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
      • 15.1.4.3.4 Other developments
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product/Service launches
      • 15.1.5.3.2 Expansions
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 QIAGEN N.V.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product/Service launches
      • 15.1.6.3.2 Deals
      • 15.1.6.3.3 Expansions
  • 15.1.7 EXACT SCIENCES CORPORATION
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product/Service launches
      • 15.1.7.3.2 Deals
  • 15.1.8 THERMO FISHER SCIENTIFIC INC.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Product/Service launches
      • 15.1.8.3.2 Deals
      • 15.1.8.3.3 Expansions
  • 15.1.9 GRAIL, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product/Service approvals
      • 15.1.9.3.2 Deals
  • 15.1.10 BIO-RAD LABORATORIES, INC.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product/Service launches
      • 15.1.10.3.2 Deals
  • 15.1.11 SYSMEX CORPORATION
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products/Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Deals
      • 15.1.11.3.2 Expansions
  • 15.1.12 MDXHEALTH
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products/Services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Deals
  • 15.1.13 PERSONALIS, INC.
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products/Services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Product/Service launches
      • 15.1.13.3.2 Deals
  • 15.1.14 THE MENARINI GROUP
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products/Services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product/Service launches
      • 15.1.14.3.2 Deals
• 15.2 OTHER PLAYERS
  • 15.2.1 NEOGENOMICS LABORATORIES
  • 15.2.2 ANGLE PLC
  • 15.2.3 LABCORP HOLDINGS INC.
  • 15.2.4 BIO-TECHNE
  • 15.2.5 MESA LABS, INC.
  • 15.2.6 MEDGENOME
  • 15.2.7 LUNGLIFE AI, INC.
  • 15.2.8 STRAND
  • 15.2.9 VORTEX BIOTECH HOLDINGS
  • 15.2.10 FREENOME HOLDINGS, INC.
  • 15.2.11 LUCENCE HEALTH INC.
  • 15.2.12 NEW DAY DIAGNOSTICS, LLC

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS

List of Tables

• TABLE 1 LIQUID BIOPSY MARKET: KEY DATA FROM PRIMARY SOURCES
• TABLE 2 LIQUID BIOPSY MARKET: RISK ASSESSMENT ANALYSIS
• TABLE 3 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022)
• TABLE 4 PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS. 2035 VS. 2050, BY REGION
• TABLE 5 INDICATIVE SELLING PRICING TREND OF LIQUID BIOPSY PRODUCTS, 2023-2025
• TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023-2025
• TABLE 7 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, BY REGION, 2023-2025
• TABLE 8 LIQUID BIOPSY MARKET: LIST OF KEY PATENTS
• TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 11 LIQUID BIOPSY MARKET: ROLE IN THE ECOSYSTEM
• TABLE 12 LIQUID BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 18 EUROPE: CLASSIFICATION OF DEVICES
• TABLE 19 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 20 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%)
• TABLE 22 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS, BY RANK
• TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
• TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 25 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 26 KEY ASSAY KITS CURRENTLY OFFERED
• TABLE 27 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 29 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 30 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 31 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 32 KEY INSTRUMENTS CURRENTLY OFFERED
• TABLE 33 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 34 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 35 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 36 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 37 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 39 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 41 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 42 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 43 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 44 KEY CTDNA PRODUCTS CURRENTLY AVAILABLE
• TABLE 45 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 46 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 48 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 49 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 50 KEY CELL-FREE DNA PRODUCTS CURRENTLY AVAILABLE
• TABLE 51 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 EUROPE: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 55 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 56 KEY CTC PRODUCTS CURRENTLY AVAILABLE
• TABLE 57 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 58 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 60 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 62 KEY EXTRACELLULAR VESICLE PRODUCTS CURRENTLY AVAILABLE
• TABLE 63 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 64 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 EUROPE: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 67 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 OTHER CIRCULATING BIOMARKER PRODUCTS CURRENTLY AVAILABLE
• TABLE 69 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 70 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 75 KEY NGS-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 76 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 77 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 EUROPE: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 81 KEY PCR & MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 82 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 83 NORTH AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 84 EUROPE: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 LATIN AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 87 LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 88 GLOBAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2045, BY REGION
• TABLE 89 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 90 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 91 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 92 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 93 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 95 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
• TABLE 96 KEY LIQUID BIOPSY PRODUCTS FOR LUNG CANCER
• TABLE 97 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 98 NORTH AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 99 EUROPE: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 LATIN AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
• TABLE 103 KEY LIQUID BIOPSY PRODUCTS FOR BREAST CANCER
• TABLE 104 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 105 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 EUROPE: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
• TABLE 110 KEY LIQUID BIOPSY PRODUCTS FOR COLORECTAL CANCER
• TABLE 111 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 112 NORTH AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 113 EUROPE: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 115 LATIN AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 116 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
• TABLE 117 KEY LIQUID BIOPSY PRODUCTS FOR PROSTATE CANCER
• TABLE 118 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 119 NORTH AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 120 EUROPE: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 121 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 122 LATIN AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 123 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2035 VS. 2050
• TABLE 124 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 125 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 126 EUROPE: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 127 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 129 GLOBAL INCIDENCE OF OTHER CANCERS, 2022 VS. 2050
• TABLE 130 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 131 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 132 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 133 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 135 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 136 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 137 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 138 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 139 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 140 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 141 KEY NIPT LIQUID BIOPSY PRODUCTS
• TABLE 142 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 143 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 144 EUROPE: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 145 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 146 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 147 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 148 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 149 EUROPE: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 150 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 151 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 152 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 153 NORTH AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 154 EUROPE: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 155 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 156 LATIN AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 157 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 158 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 159 NORTH AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 160 EUROPE: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 161 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 162 LATIN AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 163 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 164 NORTH AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 165 EUROPE: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 166 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 167 LATIN AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 168 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 169 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 170 EUROPE: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 171 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 172 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 173 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 174 NORTH AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 175 EUROPE: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 176 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 177 LATIN AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 178 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 179 LIQUID BIOPSY SAMPLES & APPLICATIONS
• TABLE 180 KEY BLOOD SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 181 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 182 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 183 EUROPE: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 184 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 185 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 186 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 187 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 188 EUROPE: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 189 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 190 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 191 LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 192 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 193 NORTH AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 194 EUROPE: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 195 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 196 LATIN AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 197 LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 198 NORTH AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 199 EUROPE: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 200 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 201 LATIN AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 202 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 203 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 204 EUROPE: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 205 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 206 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 207 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 208 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 209 EUROPE: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 210 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 211 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 212 LIQUID BIOPSY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 213 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022 VS. 2050
• TABLE 214 NORTH AMERICA: MACROECONOMIC INDICATORS
• TABLE 215 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 216 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 217 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 218 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 219 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 220 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 221 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 222 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 223 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 224 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 225 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 226 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 227 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 228 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 229 US: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 230 US: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 231 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 232 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 233 US: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 234 US: TOTAL NUMBER OF WOMEN WHO UNDERGO NIPT TESTING, 2023-2030 (MILLION UNITS)
• TABLE 235 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 236 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 237 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 238 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 239 CANADA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 240 CANADA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 241 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 242 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 243 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 244 EUROPE: MACROECONOMIC INDICATORS
• TABLE 245 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 246 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 247 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 248 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 249 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 250 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 251 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 252 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 253 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 254 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 255 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 256 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 257 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 258 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 259 GERMANY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 260 GERMANY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 261 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 262 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 263 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 264 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 265 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 266 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 267 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 268 UK: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 269 UK: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 270 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 271 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 272 UK: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 273 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 274 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 275 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 276 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 277 FRANCE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 278 FRANCE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 279 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 280 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 281 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 282 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 283 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 284 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 285 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 286 ITALY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 287 ITALY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 288 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 289 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 290 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 291 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 292 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 293 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 294 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 295 SPAIN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 296 SPAIN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 297 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 298 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 299 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 300 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 301 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 302 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 303 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 304 REST OF EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 305 REST OF EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 306 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 307 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 308 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 309 ASIA PACIFIC: MACROECONOMIC INDICATORS
• TABLE 310 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 311 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 312 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 313 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 314 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 315 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 316 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 317 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 318 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 319 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 320 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 321 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 322 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 323 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 324 CHINA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 325 CHINA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 326 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 327 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 328 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 329 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 330 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 331 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 332 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 333 JAPAN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 334 JAPAN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 335 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 336 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 337 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 338 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 339 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 340 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 341 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 342 INDIA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 343 INDIA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 344 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 345 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 346 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 347 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 348 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 349 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 350 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 351 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 352 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 353 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 354 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 355 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 356 LATIN AMERICA: MACROECONOMIC INDICATORS
• TABLE 357 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 358 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 359 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 360 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 361 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 362 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 363 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 364 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 365 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 366 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 367 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 368 BRAZIL: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 369 BRAZIL: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 370 BRAZIL: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 371 BRAZIL: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 372 BRAZIL: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 373 BRAZIL: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 374 BRAZIL: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 375 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 376 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 377 MEXICO: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 378 MEXICO: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 379 MEXICO: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 380 MEXICO: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 381 MEXICO: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 382 MEXICO: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 383 MEXICO: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 384 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 385 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 386 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 387 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 388 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 389 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 390 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 391 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 392 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 393 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 394 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
• TABLE 395 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 396 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023-2030 (USD MILLION)
• TABLE 397 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 398 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 399 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 400 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 401 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 402 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 403 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 404 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN LIQUID BIOPSY MARKET, JANUARY 2021-JUNE 2025
• TABLE 405 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
• TABLE 406 LIQUID BIOPSY MARKET: REGION FOOTPRINT
• TABLE 407 LIQUID BIOPSY MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 408 LIQUID BIOPSY MARKET: APPLICATION FOOTPRINT
• TABLE 409 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 410 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE
• TABLE 411 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION
• TABLE 412 LIQUID BIOPSY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 413 LIQUID BIOPSY MARKET: DEALS, JANUARY 2021-JUNE 2025
• TABLE 414 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 415 NATERA, INC.: COMPANY OVERVIEW
• TABLE 416 NATERA, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 417 NATERA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 418 NATERA, INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 419 NATERA, INC.: OTHER DEVELOPMENTS, JANUARY 2021- JUNE 2025
• TABLE 420 GUARDANT HEALTH: COMPANY OVERVIEW
• TABLE 421 GUARDANT HEALTH: PRODUCTS/SERVICES OFFERED
• TABLE 422 GUARDANT HEALTH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 423 GUARDANT HEALTH: DEALS, JANUARY 2021-JUNE 2025
• TABLE 424 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
• TABLE 425 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 426 MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 427 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 428 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 429 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 430 ILLUMINA, INC.:PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 431 ILLUMINA, INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 432 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 433 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2025
• TABLE 434 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 435 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 436 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 437 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 438 QIAGEN N.V.: COMPANY OVERVIEW
• TABLE 439 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
• TABLE 440 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 441 QIAGEN N.V.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 442 QIAGEN: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 443 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
• TABLE 444 EXACT SCIENCES CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 445 EXACT SCIENCES CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 446 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021-JUNE 2025
• TABLE 447 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 448 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
• TABLE 449 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 450 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 451 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 452 GRAIL, INC.: COMPANY OVERVIEW
• TABLE 453 GRAIL, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 454 GRAIL, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 455 GRAIL, INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 456 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 457 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 458 BIO-RAD LABORATORIES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 459 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 460 SYSMEX CORPORATION: COMPANY OVERVIEW
• TABLE 461 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 462 SYSMEX CORPORATION: DEALS, JANUARY 2021-JUNE 2025
• TABLE 463 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 464 MDXHEALTH: COMPANY OVERVIEW
• TABLE 465 MDXHEALTH: PRODUCTS/SERVICES OFFERED
• TABLE 466 MDXHEALTH: DEALS, JANUARY 2021-JUNE 2025
• TABLE 467 PERSONALIS, INC.: COMPANY OVERVIEW
• TABLE 468 PERSONALIS, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 469 PERSONALIS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 470 PERSONALIS, INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 471 THE MENARINI GROUP: COMPANY OVERVIEW
• TABLE 472 THE MENARINI GROUP: PRODUCTS/SERVICES OFFERED
• TABLE 473 THE MENARINI GROUP: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 474 THE MENARINI GROUP: DEALS, JANUARY 2021-JUNE 2025
• TABLE 475 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
• TABLE 476 ANGLE PLC: COMPANY OVERVIEW
• TABLE 477 LABCORP HOLDINGS INC.: COMPANY OVERVIEW
• TABLE 478 BIO-TECHNE: COMPANY OVERVIEW
• TABLE 479 MESA LABS, INC.: COMPANY OVERVIEW
• TABLE 480 MEDGENOME: COMPANY OVERVIEW
• TABLE 481 LUNGLIFE AI, INC.: COMPANY OVERVIEW
• TABLE 482 STRAND: COMPANY OVERVIEW
• TABLE 483 VORTEX BIOTECH HOLDINGS: COMPANY OVERVIEW
• TABLE 484 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW
• TABLE 485 LUCENCE HEALTH INC.: COMPANY OVERVIEW
• TABLE 486 NEW DAY DIAGNOSTICS, LLC: COMPANY OVERVIEW

List of Figures

• FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
• FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
• FIGURE 8 DATA TRIANGULATION METHODOLOGY
• FIGURE 9 LIQUID BIOPSY MARKET: PARAMETRIC ASSUMPTIONS ANALYSIS
• FIGURE 10 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 11 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 12 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 LIQUID BIOPSY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
• FIGURE 18 INCREASING INCIDENCE OF CANCER AND ADVANCES IN LIQUID BIOPSY TECHNOLOGIES TO PROPEL MARKET
• FIGURE 19 ASSAY KITS SEGMENT IS EXPECTED TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 20 CIRCULATING TUMOR DNA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 22 CANCER APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 24 BLOOD SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 25 REFERENCE LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 26 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 27 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 28 PATENT ANALYSIS FOR LIQUID BIOPSY (JANUARY 2015-DECEMBER 2024)
• FIGURE 29 VALUE CHAIN ANALYSIS OF LIQUID BIOPSY MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES
• FIGURE 30 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 31 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
• FIGURE 32 LIQUID BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 33 LIQUID BIOPSY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIQUID BIOPSY PRODUCTS
• FIGURE 35 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS
• FIGURE 36 NUMBER OF DEALS & FUNDING ACTIVITIES IN LIQUID BIOPSY MARKET
• FIGURE 37 MARKET POTENTIAL OF AI IN LIQUID BIOPSY MARKET
• FIGURE 38 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
• FIGURE 39 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
• FIGURE 40 REVENUE ANALYSIS OF LEADING FIVE PLAYERS, 2022-2024
• FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS (2024)
• FIGURE 42 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 43 LIQUID BIOPSY MARKET: COMPANY FOOTPRINT
• FIGURE 44 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 45 EV/EBITDA OF KEY VENDORS
• FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 47 BRAND COMPARISON: PCR-BASED LIQUID BIOPSY ASSAYS
• FIGURE 48 NATERA, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2024)
• FIGURE 50 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 53 QIAGEN N.V.: COMPANY SNAPSHOT (2024)
• FIGURE 54 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
• FIGURE 56 GRAIL, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 58 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 59 MDXHEALTH: COMPANY SNAPSHOT (2024)
• FIGURE 60 PERSONALIS, INC.: COMPANY SNAPSHOT (2024)